Jan Hendriks has over 25 years experience in international cooperation and technology transfer in public health. After graduation as a biologist he completed a MSc in immunology in Amsterdam. Thereafter he worked for several years for PAHO on cell mediated immunological aspects of sickle cell anemia in Jamaica and on cutaneous leishmanisis at the Fiocruz Institute in Brazil. Later he managed various laboratory/science cooperation projects between the University of Amsterdam and institutions in Vietnam, before joining the National Institute of Public Health and the Environment (RIVM) in Bilthoven as senior advisor public health. In 2000 he successfully organized with WHO in Bilthoven the pre-establishment meeting of the Developing Country Vaccine Manufacturers' Network (DCVMN) and he has been actively involved in the evolution of this Network since. After a secondment to the European Commission in Luxembourg to work on European policies and cooperation on emergency vaccines (smallpox and pandemic influenza), he returned to Bilthoven, where he is currently the International Account Manager of the Vaccinology Unit within RIVM. He has (co-authored) about 40 peer-reviewed papers in the field of infectious diseases, vaccinology and international cooperation.
Blogged on behalf of Milana Shapira and Sophia Doll
Dr. Jan Hendriks discussed the past, present and future of the place held by developing countries in the international vaccine market. The BRICs in particular are reshaping the global health industry, increasing their investment and desire to play a major role. Brazil for example manufactures 50% of their vaccines and is working towards a level of self-sufficiency. China on the other hand is expected to have their own pre-qualified vaccine in the near future.
Technology transfers have played a crucial role in facilitating these changes.
Lessons learned for the technology transfers internationally:
Â· How little attention to direct knowledge and technology transfer leads to a decline in the number of domestic and regional vaccine manufacturers in all parts of the world
Â· The importance of technical know-how and vaccine production capacity in developing countries in preventing pandemic outbreaks
Â· Case studies to illustrate examples and lessons learned for the technology transfers in low and middle income countries
Tell us what you think in the space provided below!
The presentations from the event will be made available from the 1st November.
For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation